
Aurinia Pharmaceuticals Inc: shareholders and insiders
Price
$15.13
November 18, 2026Market cap $2.0B
What Ploutos Investor adds for Aurinia Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Nov 16, 2026, from their own Form 4 filings.
Insider trades start on January 29, 2021
Until lately Aurinia Pharmaceuticals was a foreign company listed in the US. Officers of foreign companies do not report their purchases and sales, so there are none before. They are not missing on our side: they were never filed.
- Until 2020Foreign company (annual report on 20-F)
- February 2021Becomes a US filer (annual report on 10-K)
- January 29, 2021The first insider trade report (Form 4)
Bought on the market
$25M
1 person
Sold on the market
$735.9K
1 person
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan0%
- The rest100%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $25M by 1 person·sold $735.9K by 1 person
- 2025: no buys, no sales
- 2026: bought $25M by 1 person, sold $735.9K by 1 person
- Nov 13, 2026Stephen P. RobertsonChief Legal OfficerKind
- Sep 10, 2026Stephen P. RobertsonChief Legal OfficerKind
- Aug 21, 2026Stephen P. RobertsonChief Legal OfficerKind
- Jun 2, 2026Kevin TangChief Executive OfficerKind
- Jun 1, 2026Kevin TangChief Executive OfficerKind
- Jun 1, 2026Kevin TangChief Executive OfficerKind
- May 29, 2026Kevin TangChief Executive OfficerKind
- May 29, 2026Kevin TangChief Executive OfficerKind
- Mar 3, 2026Kevin TangKind
- Mar 2, 2026Kevin TangKind
- Mar 2, 2026Kevin TangKind
- Feb 27, 2026Kevin TangKind
- Feb 27, 2026Kevin TangKind
- Feb 27, 2026Kevin TangKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | Stephen P. RobertsonChief Legal Officer | 11.9K | $15.97 | $189.5K | Form 4 | |
| Sep 10, 2026 | Stephen P. RobertsonChief Legal Officer | 11.9K | $15.95 | $190.4K | Form 4 | |
| Aug 21, 2026 | Stephen P. RobertsonChief Legal Officer | 21.0K | $16.97 | $355.9K | Form 4 | |
| Jun 2, 2026 | Kevin TangChief Executive Officer | 206.0K | $15.28 | $3.1M | Form 4 | |
| Jun 1, 2026 | Kevin TangChief Executive Officer | 343.5K | $15.28 | $5.2M | Form 4 | |
| Jun 1, 2026 | Kevin TangChief Executive Officer | 99 | $15.34 | $1.5K | Form 4 | |
| May 29, 2026 | Kevin TangChief Executive Officer | 2,299 | $15.35 | $35.3K | Form 4 | |
| May 29, 2026 | Kevin TangChief Executive Officer | 262.7K | $15.31 | $4.0M | Form 4 | |
| Mar 3, 2026 | Kevin Tang | 184.2K | $14.22 | $2.6M | Form 4 | |
| Mar 2, 2026 | Kevin Tang | 115.8K | $14.21 | $1.6M | Form 4 | |
| Mar 2, 2026 | Kevin Tang | 83.6K | $14.33 | $1.2M | Form 4 | |
| Feb 27, 2026 | Kevin Tang | 300.0K | $13.90 | $4.2M | Form 4 | |
| Feb 27, 2026 | Kevin Tang | 1,600 | $14.38 | $23.0K | Form 4 | |
| Feb 27, 2026 | Kevin Tang | 214.8K | $14.12 | $3.0M | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 2, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by AUPH's officers and directors from 2021 up to November 18, 2025, 5 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Tang Capital Managementwith 5 more personsCommon Shares, no par valueShare of class10.0%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Tang Capital Managementwith 5 more personsCommon Shares, no par value | 10.0% | 13.04M | Jun 4, 20264 filings since Mar 4, 2025 | 13D/A |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
Tang Capital Management10.0%From the filing of Jun 4, 2026
Item 4 of the Original Schedule 13D is hereby amended and restated by replacing the text thereof in its entirety with the following: The Reporting Persons' acquisition was made for investment purposes. In accordance with applicable securities laws, the Reporting Persons may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments (collectively, "Securities") of the Issuer in the open market or otherwise, and reserves the right to dispose of any or all of its Securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the Securities, the whole depending…
From the filing of Jun 4, 2026
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Renaissance TechnologiesIn the quarter-7.5%
- Point72 (Cohen)In the quarter
- Citadel Advisors (Griffin)In the quarter+237%
- D.E. ShawIn the quarter-52%
- AQR CapitalIn the quarter+29%
- Millennium Mgmt (Englander)In the quarter-93%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Renaissance Technologies | 1.43M | -7.5% | $23M | 0.03% |
| Point72 (Cohen) | 223.9K | $3.6M | 0.01% | |
| Citadel Advisors (Griffin) | 811.2K | +237% | $13M | 0.01% |
| D.E. Shaw | 671.5K | -52% | $11M | 0.01% |
| AQR Capital | 1.22M | +29% | $20M | 0.01% |
| Millennium Mgmt (Englander) | 16.9K | -93% | $300.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 5.85% of its shares outstanding were held short, -1.8% since the report before.
- Shares held short
- 7.78M
- 5.85%
- Since the report before7.92M on Sep 30, 2026
- -1.8%
- 9.0
- 868.5K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 88%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 17.28M
- Nov 15, 2023: Shares held short 17.19M
- Nov 30, 2023: Shares held short 17.11M
- Dec 15, 2023: Shares held short 16.32M
- Dec 29, 2023: Shares held short 15.57M
- Jan 12, 2024: Shares held short 16.39M
- Jan 31, 2024: Shares held short 18.53M
- Feb 15, 2024: Shares held short 16.85M
- Feb 29, 2024: Shares held short 12.10M
- Mar 15, 2024: Shares held short 10.65M
- Mar 28, 2024: Shares held short 12.24M
- Apr 15, 2024: Shares held short 11.39M
- Apr 30, 2024: Shares held short 10.26M
- May 15, 2024: Shares held short 11.53M
- May 31, 2024: Shares held short 9.21M
- Jun 14, 2024: Shares held short 10.18M
- Jun 28, 2024: Shares held short 10.32M
- Jul 15, 2024: Shares held short 8.70M
- Jul 31, 2024: Shares held short 9.84M
- Aug 15, 2024: Shares held short 8.48M
- Aug 30, 2024: Shares held short 8.71M
- Sep 13, 2024: Shares held short 7.58M
- Sep 30, 2024: Shares held short 7.24M
- Oct 15, 2024: Shares held short 7.19M
- Oct 31, 2024: Shares held short 7.34M
- Nov 15, 2024: Shares held short 6.88M
- Nov 29, 2024: Shares held short 6.22M
- Dec 13, 2024: Shares held short 5.53M
- Dec 31, 2024: Shares held short 5.79M
- Jan 15, 2025: Shares held short 7.48M
- Jan 31, 2025: Shares held short 9.39M
- Feb 14, 2025: Shares held short 9.97M
- Feb 28, 2025: Shares held short 11.51M
- Mar 14, 2025: Shares held short 11.44M
- Mar 31, 2025: Shares held short 11.49M
- Apr 15, 2025: Shares held short 10.94M
- Apr 30, 2025: Shares held short 11.25M
- May 15, 2025: Shares held short 10.88M
- May 30, 2025: Shares held short 10.50M
- Jun 13, 2025: Shares held short 10.53M
- Jun 30, 2025: Shares held short 10.02M
- Jul 15, 2025: Shares held short 10.63M
- Jul 31, 2025: Shares held short 9.16M
- Aug 15, 2025: Shares held short 9.06M
- Aug 29, 2025: Shares held short 8.93M
- Sep 15, 2025: Shares held short 8.98M
- Sep 30, 2025: Shares held short 9.16M
- Oct 15, 2025: Shares held short 8.39M
- Oct 31, 2025: Shares held short 8.32M
- Nov 14, 2025: Shares held short 8.53M
- Nov 28, 2025: Shares held short 8.44M
- Dec 15, 2025: Shares held short 8.39M
- Dec 31, 2025: Shares held short 8.34M
- Jan 15, 2026: Shares held short 8.73M
- Jan 30, 2026: Shares held short 9.16M
- Feb 13, 2026: Shares held short 9.46M
- Feb 27, 2026: Shares held short 9.75M
- Mar 13, 2026: Shares held short 10.16M
- Mar 31, 2026: Shares held short 10.81M
- Apr 15, 2026: Shares held short 9.11M
- Apr 30, 2026: Shares held short 8.89M
- May 15, 2026: Shares held short 9.02M
- May 29, 2026: Shares held short 8.82M
- Jun 15, 2026: Shares held short 9.25M
- Jun 30, 2026: Shares held short 9.59M
- Jul 15, 2026: Shares held short 9.71M
- Jul 31, 2026: Shares held short 9.53M
- Aug 14, 2026: Shares held short 9.62M
- Aug 31, 2026: Shares held short 8.98M
- Sep 15, 2026: Shares held short 8.58M
- Sep 30, 2026: Shares held short 7.92M
- Oct 15, 2026: Shares held short 7.78M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading34.2% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 34.2% of the shares in the reported trades were short sales, against 45.0% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 34.2%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 45.0%
- Change
- -10.8 pts
- Short sales a dayon average, of 407.4K shares
- 139.3K
- More than atof 3,656 US-listed companies, same days
- 9%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 53.5%
- Oct 13, 2026: Short sales 56.9%
- Oct 14, 2026: Short sales 37.7%
- Oct 15, 2026: Short sales 46.2%
- Oct 16, 2026: Short sales 50.3%
- Oct 19, 2026: Short sales 53.4%
- Oct 20, 2026: Short sales 28.1%
- Oct 21, 2026: Short sales 52.5%
- Oct 22, 2026: Short sales 41.2%
- Oct 23, 2026: Short sales 63.9%
- Oct 26, 2026: Short sales 41%
- Oct 27, 2026: Short sales 58.7%
- Oct 28, 2026: Short sales 29.6%
- Oct 29, 2026: Short sales 26.6%
- Oct 30, 2026: Short sales 31.3%
- Nov 2, 2026: Short sales 42.3%
- Nov 3, 2026: Short sales 44.5%
- Nov 4, 2026: Short sales 30%
- Nov 5, 2026: Short sales 38.8%
- Nov 6, 2026: Short sales 32.2%
- Nov 9, 2026: Short sales 40.3%
- Nov 10, 2026: Short sales 34.7%
- Nov 11, 2026: Short sales 20.9%
- Nov 12, 2026: Short sales 28.9%
- Nov 13, 2026: Short sales 33.7%
- Nov 16, 2026: Short sales 33.1%
- Nov 17, 2026: Short sales 43.2%
- Nov 18, 2026: Short sales 39.8%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Kevin TangChief Executive OfficerDirectly–
- Peter GreenleafChief Executive OfficerDirectly1.79M
- Matthew Maxwell DonleyChief Operating OfficerDirectly680.5K
- Joseph M MillerChief Financial OfficerDirectly577.4K
- Stephen P. RobertsonChief Legal OfficerDirectly577.0K
- Scott Michael HabigChief Commercial OfficerDirectly456.3K
- Volker KnappertzEVP, Research and DevelopmentDirectly319.1K
- Greg KeenanChief Medical OfficerDirectly133.5K
- David R.W. JayneDirectorDirectly44.4K
- Daniel BillenDirectorDirectly28.1K
- R. Hector MacKay-DunnDirectorDirectly18.6K
- Brinda BalakrishnanDirectorDirectly17.5K
- Jeffrey Allen BaileyDirectorDirectly13.4K
- Jill LeversageDirectorDirectly12.9K
- Karen L. SmithDirectorDirectly12.7K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Kevin TangChief Executive Officer | – | 13.04M | Jun 2, 2026 | Form 4 |
| Peter GreenleafChief Executive Officer | 1.79M | – | Mar 4, 2025 | Form 4 |
| Matthew Maxwell DonleyChief Operating Officer | 680.5K | – | Mar 4, 2025 | Form 4 |
| Joseph M MillerChief Financial Officer | 577.4K | – | Mar 4, 2025 | Form 4 |
| Stephen P. RobertsonChief Legal Officer | 577.0K | – | Nov 13, 2026 | Form 4 |
| Scott Michael HabigChief Commercial Officer | 456.3K | – | Aug 6, 2024 | Form 4 |
| Volker KnappertzEVP, Research and Development | 319.1K | – | Feb 27, 2024 | Form 4 |
| Greg KeenanChief Medical Officer | 133.5K | – | Aug 1, 2025 | Form 4 |
| David R.W. JayneDirector | 44.4K | – | May 21, 2024 | Form 4 |
| Daniel BillenDirector | 28.1K | – | May 21, 2024 | Form 4 |
| R. Hector MacKay-DunnDirector | 18.6K | – | May 21, 2024 | Form 4 |
| Brinda BalakrishnanDirector | 17.5K | – | May 21, 2024 | Form 4 |
| Jeffrey Allen BaileyDirector | 13.4K | – | Nov 11, 2024 | Form 4 |
| Jill LeversageDirector | 12.9K | – | May 21, 2024 | Form 4 |
| Karen L. SmithDirector | 12.7K | – | Nov 11, 2024 | Form 4 |
A lower bound: it counts only the 15 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IBBiShares Biotechnology ETFWeight in the fund0.15%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.12%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.09%
- IWMiShares Russell 2000 ETFWeight in the fund0.06%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.06%
- VHTVanguard Health Care Index FundWeight in the fund0.02%
- ONEQFidelity Nasdaq Composite Index ETFWeight in the fund0.01%
- SPDWState Street(R) SPDR(R) Portfolio Developed World ex-US ETFWeight in the fund0.01%
- AVUSAvantis U.S. Equity ETFWeight in the fund0.00%
- IWViShares Russell 3000 ETFWeight in the fund0.00%
10 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 242
- Q4 2025: Managers 257
- Q1 2026: Managers 261
- Q2 2026: Managers 281
Institutional investors by quarter
The fund managers holding AUPH, quarter by quarter, from Q3 2014 to Q2 2025, 44 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 281 managers held 78.07M shares, worth $1.3B. During the quarter 49 opened a position, 29 closed one, 103 added and 78 trimmed.
The largest holders, Q2 2026
- Tang Capital ManagementIn the quarter+6.7%
- BlackRockIn the quarter+4.4%
- Goldman Sachs GroupIn the quarter+292%
- NEA ManagementIn the quarter
- Two Sigma InvestmentsIn the quarter+1.1%
- Arrowstreet Capital, Limited PartnershipIn the quarter-0.6%
- State StreetIn the quarter+2.5%
- Morgan StanleyIn the quarter+3.4%
- Marshall WaceIn the quarter+9.0%
- Geode Capital ManagementIn the quarter+11%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Tang Capital Management | 13.04M | +6.7% | $221M |
| BlackRock | 8.19M | +4.4% | $139M |
| Goldman Sachs Group | 5.62M | +292% | $95M |
| NEA Management | 3.97M | $67M | |
| Two Sigma Investments | 3.47M | +1.1% | $59M |
| Arrowstreet Capital, Limited Partnership | 3.26M | -0.6% | $55M |
| State Street | 2.59M | +2.5% | $44M |
| Morgan Stanley | 2.31M | +3.4% | $39M |
| Marshall Wace | 2.04M | +9.0% | $35M |
| Geode Capital Management | 1.70M | +11% | $29M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Aurinia Pharmaceuticals's filings show?
Who buys and sells is one part of Aurinia Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have AUPH's insiders bought or sold?
From Jun 2, 2026 to Nov 16, 2026 Aurinia Pharmaceuticals's insiders bought $12M and sold $735.9K of shares on the market. 0% of the sales were under set 10b5-1 plans.
Which well-known managers hold AUPH?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was Renaissance Technologies's, worth $23M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.